The new technique is now the 'prime candidate' for potential clinical trials, raising hopes that for the first time, a ...

It can take years for prostate cancer to turn castration-resistant, when cancer cells stop responding to hormonal therapy.

People live on average a little over two years after an mCRPC diagnosis. Find statistics here and learn how treatment prolongs survival.

Fellow Health, a company focused on advancing male reproductive health through patient-centric testing solutions, today announced the presentation of four posters at the American Urological ...

A newly published study involving researchers from Karolinska Institutet indicates that prostate cancer can be diagnosed at ...

Complete response (CR) observed in 79% (26/33) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who completed the Induction Treatment Phase (ITP) of the ENLIGHTED Phase 3 ...

About five years ago, Lowe began experiencing concerning symptoms, such as blood in his bowel movements. He knew he had a ...

Artificial Intelligence (AI) is no longer a futuristic idea in healthcare; it is reshaping the industry right now, and 2025 ...

Key takeaways Medicare Part D reforms under the Inflation Reduction Act now cap annual out-of-pocket drug costs at $2,000, ...

Neoadjuvant PD-1 blockade with dostarlimab achieved high rates of organ preservation in patients with early-stage mismatch ...

It is better for doctors and for the healthcare system when more people are sick and rely on medical interventions.